Results 21 to 30 of about 8,038 (216)

Gastrointestinal involvement in patients with vasculitis: IgA vasculitis and eosinophilic granulomatosis with polyangiitis

open access: yesEndoscopy International Open, 2019
Background and study aims Among vasculitides, IgA vasculitis (IgAV) and eosinophilic granulomatosis with polyangiitis (EGPA) frequently damage the gastrointestinal tract.
Keisuke Kawasaki   +15 more
doaj   +1 more source

Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

open access: yes, 2022
Objectives Patients affected by eosinophilic granulomatosis with polyangiitis (EGPA) display an increased risk of atherothrombotic events compared with the general population.
Maria Letizia Urban   +25 more
core   +1 more source

Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA [PDF]

open access: yesJournal of Investigational Allergy and Clinical Immunology, 2021
n ...
Bormioli, S   +9 more
openaire   +2 more sources

Otologic and rhinologic manifestations of EGPA [PDF]

open access: yes, 2016
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic autoimmune disease that manifests as asthma, recurrent sinusitis and peripheral eosinophilia.
Morita, Shinya   +6 more
core   +1 more source

Update on eosinophilic granulomatosis with polyangiitis

open access: yesAllergology International, 2019
Eosinophilic granulomatosis with polyangiitis (EGPA) (formerly Churg-Strauss syndrome) is a rare form of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small to medium-size ...
Shunsuke Furuta   +2 more
doaj   +1 more source

Insights from Social Media on the Patient Experience of Living With Rare Eosinophil-Driven Diseases

open access: yesJournal of Patient Experience, 2022
Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are driven by persistently high eosinophil numbers, causing damage to tissues and organs.
Mary Jo Strobel   +6 more
doaj   +1 more source

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis

open access: yesRespiratory Medicine Case Reports, 2022
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents.
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Neurological Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA): The Roles of History and Physical Examinations in the Diagnosis of EGPA

open access: yesInternal Medicine, 2017
Objective To investigate the clinical symptoms, the physical and neurological findings, and the clinical course of neurological complications in eosinophilic granulomatosis with polyangiitis (EGPA). Methods A retrospective chart review of EGPA cases managed by two referral hospitals was performed, with a focus on the neurological findings.
Oiwa, Hiroshi   +7 more
openaire   +3 more sources

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

open access: yesFrontiers in Pharmacology, 2022
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga   +7 more
doaj   +1 more source

The Diagnostic Challenge of Eosinophilic Granulomatosis With Polyangiitis Presenting as Acute Eosinophilic Myocarditis: Case Report and Literature Review

open access: yesFrontiers in Cardiovascular Medicine, 2022
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis involving small-to-medium-sized vessels characterized by asthma, vasculitis, and peripheral eosinophilia.
Hiroyuki Yamamoto   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy